CD8A and diffuse large B-cell lymphoma: Our findings firstly showed that SNHG14/miR-5590-3p altered CD8+ T cell activity through PD-1/PD-L1 axis, suggesting that targeting SNHG14 potentially improved the efficacy of immunotherapy in DLBCL through PD-1/PD-L1.